Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Apr;41(4):1440-6.
doi: 10.1128/JCM.41.4.1440-1446.2003.

Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001

Affiliations

Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001

M A Pfaller et al. J Clin Microbiol. 2003 Apr.

Abstract

The ARTEMIS Global Antifungal Susceptibility Program (ARTEMIS Program) was initiated in 2001 to provide focused surveillance of the activities of fluconazole and voriconazole against Candida spp. isolated from blood and other normally sterile sites. A total of 1,586 episodes of infection were detected at 61 international study sites. Overall, 57.7% of the infections were due to Candida albicans, followed by C. glabrata (14.8%), C. parapsilosis (12.5%), C. tropicalis (9.4%), C. krusei (2.7%), and C. lusitaniae (1.5%). Isolates of C. albicans, C. parapsilosis, and C. tropicalis were all highly susceptible to fluconazole (for 99% of the isolates the MICs were <or=8 microg/ml). Likewise, 99 to 100% of these species were inhibited by <or=1 microg of voriconazole per ml. Voriconazole was also active against C. glabrata (93% of the isolates were susceptible [MICs <or= 1 microg/ml]) and C. krusei (100% of the isolates were susceptible). The agar-based Etest and disk diffusion methods performed well for the testing of both fluconazole and voriconazole compared to the broth microdilution MIC reference method. These observations establish the continued importance of C. albicans as a pathogen and the sustained activity of fluconazole and the broad spectrum of activity of voriconazole and will serve as the first-year benchmark for the ARTEMIS Program. Continued surveillance and refinement of broth- and agar-based test methods will help to identify susceptibility trends and improve the laboratory capability for antifungal susceptibility testing.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Zones of inhibition around 25-μg fluconazole disks tested on Mueller-Hinton agar supplemented with 2% glucose and methylene blue (0.5 μg/ml) plotted against the MICs at 48 h determined by the reference BMD method for 1,586 isolates of Candida spp. The method of least squares was used to calculate a regression line (y = 49.6 − 1.9x; R = 0.7).
FIG. 2.
FIG. 2.
Zones of inhibition around 1-μg voriconazole disks plotted against the MICs determined at 48 h by the reference BMD method for 1,586 isolates of Candida spp. The method of least squares was used to calculate a regression line (y = 43.8 − 2.4x; R = 0.7).

References

    1. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459. - PMC - PubMed
    1. Barry, A. L., M. A. Pfaller, R. P. Rennie, P. C. Fuchs, and S. D. Brown. 2002. Precision and accuracy of fluconazole susceptibility tests by broth microdilution, Etest and disk diffusion methods. Antimicrob. Agents Chemother. 46:1781-1784. - PMC - PubMed
    1. Berrouane, Y. F., L. A. Herwaldt, and M. A. Pfaller. 1999. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J. Clin. Microbiol. 37:531-537. - PMC - PubMed
    1. Chryssanthou, E. 2001. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre Yeast One colorimetric antifungal panel with the NCCLS M27-A reference method. J. Clin. Microbiol. 39:4181-4183. - PMC - PubMed
    1. Ellis, D., D. Marriott, R. A. Hajjeh, D. Warnock, W. Meyer, and R. Barton. 2000. Epidemiology: surveillance of fungal infections. Med. Mycol. 38(Suppl. 1):173-182. - PubMed

Publication types

LinkOut - more resources